乳腺癌激素受体表达与新辅助化疗后病理完全缓解的关系(4)
[8] Gianni L，Eiermann W，Semiglazov V，et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH)：follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet Oncol，2014，15(6)：640-647.
[9] De Azambuja E，Holmes A P，Piccart-Gebhart M，et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO)：survival outcomes of a randomised，open-label，multicentre，phase 3 trial and their association with pathological complete response[J].Lancet Oncol，2014，15(10)：1137-1146.
[10] von Minckwitz G，Schneeweiss A，Loibl S，et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66)：a randomised phase 2 trial[J].Lancet Oncol，2014，15(7)：747-756.
[11] Sikov W M，Berry D A，Perou C M，et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer：CALGB 40603 (Alliance)[J].Clin Oncol，2015，33(1)：13-21.
[12]中國抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志，2019，29(8)：609-680.
(收稿日期：2020-06-24) (本文编辑：桑茹南), 百拇医药(颜翔鹏 吕艳丽 穆为民 李毅)
[9] De Azambuja E，Holmes A P，Piccart-Gebhart M，et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO)：survival outcomes of a randomised，open-label，multicentre，phase 3 trial and their association with pathological complete response[J].Lancet Oncol，2014，15(10)：1137-1146.
[10] von Minckwitz G，Schneeweiss A，Loibl S，et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto;GBG 66)：a randomised phase 2 trial[J].Lancet Oncol，2014，15(7)：747-756.
[11] Sikov W M，Berry D A，Perou C M，et al.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer：CALGB 40603 (Alliance)[J].Clin Oncol，2015，33(1)：13-21.
[12]中國抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志，2019，29(8)：609-680.
(收稿日期：2020-06-24) (本文编辑：桑茹南), 百拇医药(颜翔鹏 吕艳丽 穆为民 李毅)